Literature DB >> 25608150

Analysis of the roles of glucose transporter 1 and hexokinase 2 in the metabolism of glucose by extrahepatic bile duct cancer cells.

Sun Och Yoon1, Tae Joo Jeon, Joon Seong Park, Yong Hoon Ryu, Jae-Hoon Lee, Jung Sik Yoo, Jae Keun Kim, Dong Sup Yoon, Eun Ji Oh.   

Abstract

PURPOSE OF THE REPORT: Extrahepatic bile duct (EHD) cancer varies in uptake of FDG. The aim of the present study was to determine the role of glucose transporter (GLUT) 1 and hexokinase (HK) 2 in the glucose metabolism of EHD cancer cells using immunohistochemistry and 18F-FDG PET/CT.
METHODS: Twenty-six patients with EHD cancer who underwent baseline PET/CT and surgery were studied. Biopsies were immunohistochemically analyzed using antibodies against GLUT1 and HK2, and the expression was scored from 0 to 4 according to the percentage of stained cells. SUV and tumor-to-liver ratio (T/L ratio) were obtained from 18F-FDG PET/CT data. SUV and T/L ratio and GLUT1 and HK2 expression were compared with histological grades and tumor locations (proximal and distal EHD) to correlate glucose metabolism with the expression of GLUT1 and HK2.
RESULTS: SUV, T/L ratio, and GLUT1 and HK2 expression did not differ as a function of histological grade and tumor location. GLUT1 and HK2 were expressed in 20 (76.9%) and 22 (84.6%) of 26 tumor biopsies, respectively. The GLUT1 score, SUV, and T/L ratio increased, and the GLUT1 score, but not the HK2 score, correlated significantly with SUV (ρ = 0.648) and T/L ratio (ρ = 0.703). There was no direct correlation between the expression of GLUT1 and that of HK2 (ρ = 0.2046, P = 0.3161).
CONCLUSIONS: Although GLUT1 and HK2 regulate intracellular accumulation of FDG in many cancers, only GLUT1 expression was correlated with FDG uptake by EHD cancers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25608150     DOI: 10.1097/RLU.0000000000000640

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  8 in total

1.  Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors.

Authors:  Nandakumar Menon; Mark Mandelkern
Journal:  Dig Dis Sci       Date:  2022-07-30       Impact factor: 3.487

2.  Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signaling.

Authors:  Yang Li; Shuting Yang; Yang Liu; Shuying Yang
Journal:  MedComm (2020)       Date:  2022-04-22

3.  18F-FDG super bone marrow uptake: A highly potent indicator for the malignant infiltration.

Authors:  Mohammed Shah Alam; Lilan Fu; Yun-Yan Ren; Hu-Bing Wu; Quan-Shi Wang; Yan-Jiang Han; Wen-Lan Zhou; Hong-Sheng Li; Zhen Wang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

4.  Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT.

Authors:  Chengfang Shangguan; Guifang Gan; Jieying Zhang; Jinliang Wu; Ying Miao; Miao Zhang; Biao Li; Jun Mi
Journal:  Theranostics       Date:  2018-02-02       Impact factor: 11.556

5.  Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro.

Authors:  Tao Jiang; Min-Li Zhou; Jun Fan
Journal:  Onco Targets Ther       Date:  2018-11-06       Impact factor: 4.147

6.  Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis.

Authors:  Hans-Jonas Meyer; Andreas Wienke; Alexey Surov
Journal:  PLoS One       Date:  2019-06-17       Impact factor: 3.240

7.  A control theoretic three timescale model for analyzing energy management in mammalian cancer cells.

Authors:  Abhijit Dasgupta; Abhisek Bakshi; Nirmalya Chowdhury; Rajat K De
Journal:  Comput Struct Biotechnol J       Date:  2020-12-29       Impact factor: 7.271

8.  CPNE1 Enhances Colorectal Cancer Cell Growth, Glycolysis, and Drug Resistance Through Regulating the AKT-GLUT1/HK2 Pathway.

Authors:  Yuexia Wang; Shengli Pan; Xinhong He; Ying Wang; Haozhe Huang; Junxiang Chen; Yuhao Zhang; Zhijin Zhang; Xianju Qin
Journal:  Onco Targets Ther       Date:  2021-01-27       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.